US SEC Filings Daily Market Digest — March 19, 2026

19-03-2026

FreightCar America, Inc. (RAIL) filed a DEF 14A proxy statement for its virtual Annual Meeting of Stockholders on April 10, 2026, at 10:00 a.m. Central Time, to elect three Class III directors for three-year terms, approve on an advisory basis the compensation of Named Executive Officers, and ratify Grant Thornton LLP as independent registered public accounting firm for fiscal year 2026. The record date is February 10, 2026, with 19,062,155 shares of common stock outstanding entitled to vote. Proxy materials are being mailed on or about March 19, 2026.

• ·Meeting held virtually only via live webcast at www.meetnow.global/MFVJ6LW
• ·Voting requires 15-digit control number for proxy submission via internet, phone, or mail
• ·Quorum requires majority of shares outstanding on record date present virtually or by proxy

19-03-2026

DarioHealth Corp. reported total revenues of $22.4M for FY 2025, down 17% YoY from $27.0M, driven by a 26% decline in services to $14.9M despite an 8.5% increase in consumer hardware to $7.4M. Operating expenses fell 31% to $49.3M, resulting in a smaller operating loss of $36.7M versus $57.7M prior year, and net loss improved slightly to $41.7M from $42.7M; however, cash and equivalents dropped to $21.8M from $27.8M, total assets declined to $110.1M from $118.9M, and stockholders' equity decreased to $67.9M from $72.0M amid significant share dilution to 6.9M shares outstanding.

• ·Cash used in operating activities improved to $(25.9M) from $(38.6M) YoY.
• ·Non-GAAP adjusted loss improved to $(24.2M) from $(33.8M), a $9.6M betterment.
• ·Accumulated deficit worsened to $(452.1M) from $(390.3M).
• ·Basic and diluted loss per share improved to $10.12 from $12.27.
• ·Weighted average shares increased to 3,983K from 2,452K.

19-03-2026

RYVYL Inc. adjourned its Special Meeting of Shareholders on March 18, 2026, to vote on the planned merger with RTB Digital, Inc. (Roundtable), reconvening virtually on March 25, 2026, at 4pm EST. Approximately 99% of votes cast supported the merger, with 43% of entitled shares voted, requiring only an additional 7% in favor to approve; however, the adjournment highlights that quorum or majority threshold has not yet been met. The company urges unvoted shareholders to participate promptly via Kingsdale Advisors.

• ·Record date for Special Meeting: February 6, 2026 (unchanged)
• ·Virtual meeting link: http://www.virtualshareholdermeeting.com/RVYL2026SM
• ·Voting assistance contact: Kingsdale Advisors at 888-518-6812 or contactus@kingsdaleadvisors.com

19-03-2026

Brunswick Corporation filed a DEFA14A additional proxy statement for its annual shareholder meeting on May 6, 2026, seeking votes on the election of ten director nominees, an advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. The board recommends voting 'For' all proposals. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Vote deadline: 11:59 PM ET on May 5, 2026 (May 1, 2026 for employee plan shares)
• ·Material request deadline: April 22, 2026
• ·Proxy voting options: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com
• ·Company address: 26125 N. Riverwoods Blvd., Suite 500, Mettawa, IL 60045-3420

19-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 19, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Books Hundreds of SARA Licenses as Customers Expand After Initial Deployment.' The press release is furnished as Exhibit 99.1 and is not deemed filed or material.

• ·Filed by newsfilecorp.com
• ·Registrant details: Nevada incorporation, Commission File Number 000-55079, IRS Employer Identification No. 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220

19-03-2026

AMERICAN VANGUARD CORPORATION (as Holdings) and AMVAC CHEMICAL CORPORATION (as Borrower) entered into a Credit and Guaranty Agreement dated March 13, 2026, with Wilmington Trust, National Association as Administrative Agent and certain lenders, establishing a senior secured term loan facility with an aggregate principal amount of $225 million. The facility provides financing subject to covenants, representations, and events of default, with interest rates starting at Term SOFR plus 8.25% or Base Rate plus 7.25%, eligible to step down based on improvements in the Consolidated Total Leverage Ratio below thresholds like 4.00:1.00. No prior period financial performance data or comparisons are disclosed in the filing.

• ·Compliance Certificate due two business days after quarterly financials for fiscal quarter ending June 30, 2026, to potentially adjust Applicable Margin.
• ·ABL Facility permitted if approved by Required Lenders, secured junior to term loan on non-ABL Priority Collateral.

19-03-2026

Legence Corp. filed Amendment No. 1 to its January 2, 2026 Form 8-K to include the required audited consolidated financial statements of acquired business The Bowers Group, Inc. (Bowers) for the year ended September 30, 2025 (Exhibit 99.1), and unaudited pro forma condensed combined financial information for Legence and subsidiaries as of September 30, 2025, for the nine months ended September 30, 2025, and the year ended December 31, 2024 (Exhibit 99.2). The acquisition of 100% of Bowers' equity interests was consummated on January 2, 2026, via Legence Corp. and its subsidiary Legence Subsidiary Holdings, LLC. No specific financial metrics or performance changes are disclosed in the filing text.

• ·Auditor consent for Bowers financials provided by Lanigan Ryan, P.C. (Exhibit 23.1)
• ·Securities: Class A common stock (LGN) on Nasdaq Stock Market LLC
• ·Company headquarters: 1601 Las Plumas Avenue, San Jose, CA 95133

19-03-2026

SUNation Energy reported robust Q4 and FY 2025 financial results, with Q4 revenue surging 77% YoY to $27.2M, gross margin expanding to 40.7%, and Adjusted EBITDA reaching $4.1M versus a prior-year loss; FY revenue grew 26% YoY to $71.9M, beating the $65-70M guidance, with gross profit up 35% to $27.5M and Adjusted EBITDA at $2.5M. The company strengthened its balance sheet, ending with $7.2M liquidity, positive $1.1M working capital, and total debt reduced 57% to $8.1M from $19.1M. However, FY operating loss was still $1.7M (improved from $12.3M) and net loss $10.9M (from $15.8M), with management noting significant 2026 challenges from the Section 25D tax credit expiration.

• ·SUNation NY remained the leading solar contractor in its region with Long Island aggregate installed capacity up 29% YoY.
• ·Operating expenses declined 10.8% YoY to $29.2M in FY 2025.
• ·Cash flow from financing activities was $5.1M, used to pay down $12.6M of debt and obligations.

19-03-2026

Catalyst Pharmaceuticals, Inc. (CPRX) filed an 8-K/A on March 19, 2026, to correct a scrivener’s error in the signature date of its prior 8-K filed on March 18, 2026. The underlying event discloses a District Court for the District of New Jersey order delaying the bench trial against Hetero USA, Inc. from March 23, 2026, to May 18, 2026, concerning the validity of the company's Orange Book-listed patents for FIRDAPSE® that expire in 2032, 2034, and 2037. No other changes were made to the original filing.

• ·District Court for the District of New Jersey issued the trial delay order.
• ·Patents are Orange Book-listed.

19-03-2026

SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced on March 17, 2026, a proposed underwritten public offering of common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase up to an additional 15% of the securities. Net proceeds, along with existing cash, will primarily fund the development of clinical-stage candidate SAB-142 through ongoing and planned trials, manufacturing, regulatory activities, and general corporate purposes. The offering is subject to market conditions with no assurance of completion or final terms.

• ·Shelf registration statement on Form S-3 (No. 333-292482) filed December 29, 2025, declared effective January 7, 2026.
• ·Joint book-running managers: Jefferies, UBS Investment Bank, Citigroup, Barclays; lead manager: Chardan.

19-03-2026

Modiv Industrial, Inc. announced it will report financial results for the quarter and full year ended December 31, 2025, after market close on March 25, 2026. The company declared a quarterly dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, payable April 15, 2026, and monthly distributions of $0.10 per share on Class C Common Stock for April, May, and June 2026, equivalent to an annualized $1.20 per share. No comparative financial metrics were provided in the filing.

• ·Board authorized dividends and distributions on March 17, 2026.
• ·Series A Preferred record date: March 31, 2026.
• ·Common Stock record dates: April 30, May 29, June 30, 2026.
• ·Common Stock payment dates: May 15, June 15, July 15, 2026.

19-03-2026

Pyrophyte Acquisition Corp. (SPAC) and Sio Silica Corporation entered into the Fifth Amendment to their Business Combination Agreement dated March 13, 2026, extending the Outside Date for the Company Amalgamation from April 29, 2026 to April 29, 2027. This follows four prior amendments extending the timeline from the original BCA dated November 13, 2023. The amendment maintains all other terms of the BCA, which contemplates a SPAC Amalgamation followed by a Company Amalgamation under Alberta law.

• ·Original BCA dated November 13, 2023.
• ·First Amendment: November 12, 2024, extended Outside Date to December 31, 2024.
• ·Second Amendment: December 31, 2024, extended to April 30, 2025.
• ·Third Amendment: April 11, 2025, extended to December 31, 2025.
• ·Fourth Amendment: October 16, 2025, extended to April 29, 2026.
• ·Fifth Amendment effective March 13, 2026, filed March 19, 2026.

19-03-2026

Selectis Health, Inc. appointed Richard Huebner, age 68, as a new member of its Board of Directors effective March 12, 2026. Mr. Huebner, senior managing partner at GVC Capital LLC since 2001, has extensive experience in investment banking, compliance, and legal roles at firms including Fiserv Correspondent Services and Hanifen Imhoff Inc. He will receive an annual stipend of $30,000 under the company's Outside Directors Compensation Plan.

• ·Richard Huebner served as registered investment advisor (2000-2001), Executive Vice President at Fiserv Correspondent Services (1984-2000), and various roles at Hanifen Imhoff entities (1979-1997) and First Mid America, Inc. (1980-1983).
• ·Education: Bachelor’s degree from Hastings College (1979); Juris Doctorate from University of Nebraska (1982).

19-03-2026

News Corporation filed an 8-K on March 19, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The program authorizes repurchases up to $1B in aggregate, with daily ASX disclosures required for any transactions; Exhibits 99.1 and 99.2 contain the specific details. No actual repurchase volumes or impacts were detailed in the filing.

• ·Securities traded on The Nasdaq Global Select Market.
• ·Event date: March 18, 2026; Filing date: March 19, 2026.

19-03-2026

Gold Resource Corporation reported 2025 full-year production of 23,125 gold equivalent ounces (4,944 gold oz and 1,461,898 silver oz) from Don David Gold Mine, reflecting a YoY increase in AuEq output driven by strong Q4 performance (10,413 AuEq oz) and higher silver volumes, with realized prices of $3,657/oz gold and $45.48/oz silver, cash costs of $2,205/AuEq oz, and AISC of $2,807/AuEq oz. The company ended with $25M cash (up $23.4M YoY) and $32M working capital (up 1,424% from $2.1M), bolstered by $22.5M+ in financings including offerings and a $4M tax refund. However, gold production declined YoY, early 2025 quarters showed lower tonnes milled and AuEq output versus 2024, and total capital/exploration spend rose to $24M.

• ·DDGM received Mexican ESR award for 11th consecutive year.
• ·Sustaining investments $12.4M (up from $8.6M YoY); growth investments $11.6M (up from $2.3M YoY).
• ·January 2025 registered direct offering $2.5M; February 2025 sale of Green Light Metals interest $0.9M.
• ·September 2025 offering included 14.2M shares ($6.4M fair value) for non-cash term loan payoff.
• ·Exploration focused on grade-control drilling at Three Sisters and Arista; surface drilling started at Alta Gracia Q4 2025.

19-03-2026

On March 17, 2026, The Cannabist Company Holdings Inc. secured a further extension of a forbearance agreement from an ad hoc group of noteholders for its 9.25% Senior Secured Notes due December 31, 2028, and 9.00% Senior Secured Convertible Notes due December 31, 2028, postponing any exercise of remedies until March 25, 2026. This development signals ongoing financial stress and potential covenant issues under the amended indenture. No financial metrics or performance data were disclosed.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 321 Billerica Road, Chelmsford, Massachusetts 01824.
• ·Telephone: (978) 910-1486.
• ·No securities registered pursuant to Section 12(b) of the Act.

19-03-2026

Marker Therapeutics reported strong Phase 1 APOLLO clinical data for MT-601 with a 66% objective response rate (50% complete responses) in relapsed non-Hodgkin lymphoma and 78% in Hodgkin lymphoma, plus promising pancreatic cancer results (up to 84.6% disease control rate) published in Nature Medicine. Financially, cash stood at $17M at year-end 2025, funding operations through Q4 2026, but revenues fell 46% YoY to $3.5M, net loss widened 14% to $12.2M from $10.7M, despite R&D expenses declining 12% to $11.8M and flat G&A at $4.2M. Upcoming catalysts include APOLLO data updates and pancreatic program start in Q2 2026.

• ·Dose expansion in APOLLO enrolling relapsed DLBCL patients at 400×10⁶ cells; no DLTs or ICANS reported.
• ·Manufacturing technical transfer with Cellipont Bioservices expected Q2 2026.
• ·Supported by non-dilutive grants from NIH (R44CA291521, R44CA295168, 1R44CA285177), FDA (R01FD007272), CPRIT (DP250150, DP210042).

19-03-2026

Innventure, Inc. filed a Form S-3 registration statement on March 18, 2026, to register the resale of common stock by certain selling stockholders, consolidating three prior Form S-1 registrations (File Nos. 333-282971, 333-286558, and 333-291034). The filing covers already issued outstanding shares or those issuable upon conversion or exercise of previously disclosed securities, with no new equity issuances or stockholder dilution. The company will not receive proceeds from these resales, except potentially from its Standby Equity Purchase Agreement with YA II PN, Ltd., dated October 24, 2023, or cash exercises of certain warrants.

• ·Commission File Number: 001-42303
• ·I.R.S. Employer Identification Number: 93-4440048
• ·Prior Form S-1 File Nos.: 333-282971, 333-286558, 333-291034

19-03-2026

Global Net Lease, Inc. announced the declaration of quarterly dividends on its preferred stocks on March 19, 2026: $0.453125 per share for 7.25% Series A, $0.4296875 per share for 6.875% Series B, $0.46875 per share for 7.50% Series D, and $0.4609375 per share for 7.375% Series E, all payable on April 15, 2026 to holders of record on April 3, 2026. These dividends align with the stated coupon rates, providing expected returns to preferred shareholders.

• ·All preferred stocks listed on New York Stock Exchange
• ·Company address: 650 Fifth Avenue, 30th Floor, New York, New York 10019
• ·Telephone: (332) 265-2020

19-03-2026

argenx SE reported robust 2025 financial results with product net sales surging 90% YoY to $4.15B from $2.19B, driving total operating income up 89% to $4.25B and flipping operating profit to $1.05B from a $22M loss. However, total operating expenses increased 40% to $3.19B due to cost of sales rising 98% to $451M, R&D up 39% to $1.36B, and SG&A up 30% to $1.37B; profit grew 55% to $1.29B but the income tax benefit dropped 98% to $13M. Basic EPS rose 51% to $21.08.

• ·2025 Remuneration Policy approved at approx. 96% vs 2021 policy at 77%.
• ·Non-Executive Director annual equity grant: $400,000 in restricted shares with 4-year holding.
• ·Shares outstanding grew from 59,194,488 (Dec 31, 2023) to 61,883,306 (Dec 31, 2025).

19-03-2026

Republic Airways Holdings Inc. reported FY2025 revenues of $1,676.5M, up 13.7% YoY from $1,474.0M, with operating income rising 22.8% to $168.3M and Adjusted EBITDA surging 32.9% to $341.7M, driving net income to $76.2M (+18.0%). However, executive separation and merger-related costs jumped to $47.1M from $3.2M, total liquidity declined 1.1% to $319.9M, and net cash used in investing activities ballooned to $350.9M. In FY2024 vs FY2023, revenues grew modestly 3.1% but Adjusted EBITDA fell 12.8% to $257.2M.

• ·Net cash provided by operating activities increased 42.4% to $322.0M in FY2025 from $226.1M.
• ·Net cash used in investing activities worsened to $350.9M in FY2025 from $105.5M.
• ·Income tax expense rose 66.8% to $37.2M in FY2025.
• ·Depreciation and amortization increased 7.9% to $126.3M in FY2025.
• ·Marketable securities declined 15.3% to $162.2M in FY2025.

19-03-2026

Artius II Acquisition Inc., a SPAC, reported net income of $136k for the year ended December 31, 2025, compared to a $85k net loss for the period from inception (July 25, 2024) through December 31, 2024, driven by $8.1M interest income from the Trust Account offsetting a $7.9M operating loss that included a $6M advisory fee. Total assets grew to $228.3M primarily from $228.1M in the Trust Account following the IPO of 22M Class A shares, but shareholders' deficit widened significantly to $13.8M due to accretion of $18.8M. Cash position was minimal at $32k.

• ·IPO involved sale of public units generating $219.75M net proceeds.
• ·Founder shares: 250,000 Class B shares forfeited by Sponsor.
• ·Promissory note to related party repaid $135k in 2025.
• ·Basic and diluted EPS of $0.01 for redeemable and non-redeemable Class A shares in 2025.
• ·Class B shares EPS not applicable in 2025; prior period loss per share ($0.02).

19-03-2026

Rice Acquisition Corp 3, a SPAC, reported net income of $2.85M for the period from inception (June 6, 2025) to December 31, 2025, driven by $3.4M interest income from the Trust Account offsetting a $548K operating loss from formation and administrative costs. Total assets stood at $351.3M, primarily $348.4M cash in the Trust Account from IPO proceeds (34.5M Class A shares at $10.10 redemption value), while shareholders' deficit was $13.2M due to accretion and transaction costs. No business combination has occurred, with cash outside trust at $2.6M and ongoing liabilities including $13.4M deferred underwriting fees.

• ·IPO-related financing: $338.1M proceeds from Units net of underwriting discounts; $10.65M from Private Placement Warrants
• ·Cash flows: Net used in operations $(467.5K); investing $(345M) into Trust; financing $348.1M
• ·Non-cash: Accretion of Class A shares to redemption $28.9M; transaction costs allocated $257K

19-03-2026

United Bancorp, Inc. filed an amended Form 10-K/A for the fiscal year ended December 31, 2025, on March 19, 2026, primarily incorporating exhibits by reference including governance documents, executive change-in-control agreements, supplemental life insurance and deferred compensation plans, stock incentive plans, subordinated debt agreements, the 2025 Annual Report, insider trading policies, subsidiaries list, audit consents, and Sarbanes-Oxley certifications. Signatures were provided by CEO Scott A. Everson, CFO Randall M. Greenwood, and directors on March 18, 2026. No financial performance metrics, period-over-period comparisons, or material updates to results are detailed in the filing content.

• ·Filing covers FY 2025 (January 1, 2025 to December 31, 2025).
• ·Key exhibits include Clawback Policy (Exhibit 97) and Insider Trading Policies and Procedures (Exhibit 19).

19-03-2026

Micron Technology reported exceptional Q2 FY2026 results with revenue surging 196% YoY to $23.9B from $8.1B, gross margin expanding dramatically to $17.8B (499% YoY increase), and net income skyrocketing 771% YoY to $13.8B. For the six months ended February 26, 2026, revenue more than doubled 124% YoY to $37.5B with net income up 451% to $19.0B. The balance sheet strengthened significantly, with cash and equivalents rising 44% to $13.9B, total assets up 23% to $101.5B, and long-term debt reduced 32% to $9.6B, though inventories dipped slightly 1% QoQ.

• ·EPS diluted Q2 FY2026: $12.07 (vs $1.41 YoY, +756%)
• ·R&D expense Q2: $1.25B (up 39% YoY)
• ·Stock-based compensation expense six months: $599M
• ·Dividends declared Q2: $0.115 per share ($132M total); six months $0.23 per share ($264M total)
• ·Several senior notes repaid in period including 2028 Notes, 2029 A/B Notes, 2029 Term Loan A, 2030 Notes (October 2025/February 2026)

19-03-2026

Inception Growth Acquisition Ltd, a blank check company, withdrew $5,269.61 of interest earned from its trust account on March 16, 2026, to pay taxes, leaving approximately $2.13M remaining in the trust. This routine disclosure under Item 8.01 provides transparency on trust account activity amid ongoing operations as an emerging growth company listed on OTC Markets.

• ·Securities traded on OTC Markets Group, Inc.: IGTAU (Units), IGTA (Common Stock, $0.0001 par), IGTAW (Warrants exercisable at $11.50), IGTAR (Rights for 1/10th share)
• ·Company is an emerging growth company under Rule 405/12b-2
• ·Filing date: March 19, 2026; Event date: March 16, 2026

19-03-2026

Equinor ASA's full-year 2025 results show consolidated total revenues of $43.8B, down 2.5% YoY from $44.9B, with results of operations at $5.7B versus $7.7B in 2024 amid higher costs and lower international performance. E&P Norway delivered stable revenues up 2% to $34.4B with 2% higher entitlement production, but net operating income dipped 2%; E&P International revenues plunged 31% to $5.1B with net operating income down 83% and 14% lower equity production; while E&P USA revenues rose 9% to $4.3B on 27% production growth, net operating income fell 35% due to elevated expenses. Net capitalized costs for oil and gas activities increased to $55.2B from $51.8B.

• ·Norway average liquids price down 13% YoY to $66.8/bbl; internal gas price up 13% to $10.70/MMBtu.
• ·E&P International average liquids price down 14% YoY to $62.0/bbl.
• ·E&P USA average liquids price down 14% YoY to $55.7/bbl; internal gas price up 53% to $2.60/MMBtu.
• ·E&P Norway gas production down 2% YoY to 739 mboe/day.
• ·Additions to PP&E etc. in E&P International up >100% to $8.2B; in E&P USA down 69% to $1.2B.
• ·Africa results of operations $398M in 2025 vs $1,763M in 2024 (down 77%).